A Study of LY3561774 in Participants With Mixed Dyslipidemia
Status:
Not yet recruiting
Trial end date:
2023-11-06
Target enrollment:
Participant gender:
Summary
This a multicenter, Phase 2b, double-blind, placebo-controlled, parallel group study to
provide data on efficacy and safety of LY3561774 administered subcutaneously at various doses
in participants with mixed dyslipidemia and on a stable dose of a statin.